What type of nephritis does spaxentan treat?

Sparsentan (trade name: Filspari) is mainly used to treat primary glomerulonephritis, especially for patients with IgA nephropathy (immunoglobulin A nephropathy) who are at risk of rapid disease progression.

Sparsentan is mainly suitable for adult patients with IgA kidney disease, especially those whose urine protein to creatinine ratio (UPCR) is greater than or equal to 1.5g/g and who are at risk of rapid disease progression. IgANephropathy is one of the most common primary glomerular diseases in the world. It is characterized by the deposition of large amounts of immunoglobulin A in the glomeruli, leading to glomerular damage and dysfunction. Proteinuria is one of the main clinical manifestations of IgA nephropathy and an important predictor of renal function deterioration.

Sparsentan, as a new endothelin-angiotensin dual blocker, blocks endothelinA type (ETA) receptors and angiotensinII at the same time. Type 1 (AT1) receptor achieves effective intervention in two key pathways for the progression of IgA nephropathy. This dual blocking mechanism allows sparsentan to protect glomerular podocytes and prevent glomerulosclerosis and mesangial cell proliferation, thereby significantly reducing proteinuria and protecting renal function.

Multiple clinical trial data show that sparsentane has significant efficacy in the treatment ofIgA nephropathy. For example, in the PROTECT study, the proteinuria levels of patients in the sparsentan group dropped significantly within 36 weeks, and the reduction was significantly better than the control drug irbesartan. In addition, sparsentane can slow down the decline of kidney function and improve patients' quality of life. These findings provide strong evidence support for the application of sparsentane in the treatment of IgA nephropathy.

Sparsentane is generally well tolerated, but patients still need to be aware of possible side effects during use. Common side effects include hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, hyperkalemia, etc. In addition, some patients may also experience liver function abnormalities such as elevated transaminases. Therefore, patients should undergo detailed liver function tests before using sparsentane and monitor relevant indicators regularly during treatment. At the same time, patients should follow the doctor's guidance to use medications rationally and avoid adjusting the dosage or stopping medication on their own.